Valuation: Erasca, Inc.

Market Cap 6.39B 5.52B 5.18B 4.72B 8.87B 611B 8.99B 60.7B 23.79B 306B 24B 23.48B 1,019B P/E 2026 *
-18.7x
P/E 2027 * -29.9x
Enterprise Value 5.55B 4.79B 4.49B 4.09B 7.69B 530B 7.8B 52.65B 20.63B 266B 20.82B 20.37B 884B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.54%
1 week+0.88%
Current month+0.72%
1 month-4.64%
3 months+78.69%
6 months+46.83%
Current year+391.40%
1 week 17.3
Extreme 17.3
19.22
1 month 17.08
Extreme 17.08
19.96
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2019
Director of Finance/CFO 43 06/01/2021
Chief Tech/Sci/R&D Officer 66 09/08/2026
Director TitleAgeSince
Chairman 54 30/09/2018
Director/Board Member 79 31/05/2018
Director/Board Member 58 01/07/2018
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/06/26 Free

Director

29,888 0.0096%
29/01/26 Free

General Counsel

560,000 0.1974%
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%+0.88%+1,014.63%+628.29% 6.39B
-0.14%-1.53%+1.94%+20.07% 48.84B
+4.07%+2.43%+483.70%+623.80% 45.44B
+4.33%+0.98%+12.80%+88.53% 41.22B
+1.94%-0.31%+26.24%+12.62% 39.71B
-0.50%0.00%+20.60%+60.49% 32.6B
+0.10%-3.22% - - 16.25B
+3.22%-0.88%+30.42%+135.47% 16.67B
-0.57%-0.43%+3.36%+29.03% 14.08B
+2.35%+3.48%+82.95%+43.41% 13.68B
Average +1.43%+0.10%+186.29%+182.41% 27.49B
Weighted average by Cap. +1.80%+0.05%+125.63%+165.20%

Financials

2026 *2027 *
Net sales - -
Net income -318M -275M -258M -235M -441M -30.43B -448M -3.02B -1.18B -15.25B -1.19B -1.17B -50.72B -211M -182M -170M -155M -292M -20.13B -296M -2B -783M -10.08B -790M -773M -33.54B
Net Debt -849M -733M -687M -626M -1.18B -81.13B -1.19B -8.06B -3.16B -40.65B -3.19B -3.12B -135B -762M -658M -617M -562M -1.06B -72.83B -1.07B -7.23B -2.83B -36.49B -2.86B -2.8B -121B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
17/08/26 US$18.28 -0.54% 2,224,690
14/08/26 US$18.38 +2.91% 2,465,955
13/08/26 US$17.86 -3.88% 2,604,948
12/08/26 US$18.58 +1.47% 3,647,530
11/08/26 US$18.31 +1.05% 3,426,210
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.28USD
Average target price
23.30USD
Spread / Average Target
+27.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock